Treximet®
Migraine Without Aura
University of AarhusPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Migraine Without Aura cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 4 | BBB |
Dihydroergotamine mesylate Satsuma Pharmaceuticals, Inc. | Phase 3 | BBB |
PROPRANOLOL Norwegian University of Science and Technology | Phase 3 | BB |
METOCLOPRAMIDE Assistance Publique - Hôpitaux de Paris | Phase 4 | BB |
Rimegepant University of South Florida | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Treximet® is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →